{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-063021","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.808511+00:00","generated_at":"2026-06-08T04:44:48.515710+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sutro Biopharma Q3 2023: Revenue $16.9M, cash runway into H1 2025; luvelta data and new CSO","bullets":["Cash and investments $321.1M plus Vaxcyte shares valued at $34.0M projecting runway into first half 2025.","Q3 2023 revenue $16.9M, down from $25.1M in Q3 2022; operating expenses $60.9M vs $46.4M.","Luvelta showed encouraging anti-tumor activity in FolRα-selected endometrial cancer at ESMO 2023; AML compassionate use data at ASH 2023.","Dr. Hans-Peter Gerber appointed Chief Scientific Officer in September 2023.","REFRaME-O1 Phase 2/3 trial for platinum-resistant ovarian cancer enrollment underway; global registration discussions with FDA/EMA."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-063021","json":"https://secwatch.observer/filing/0000950170-23-063021.json","markdown":"https://secwatch.observer/filing/0000950170-23-063021.md","text":"https://secwatch.observer/filing/0000950170-23-063021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023063021/0000950170-23-063021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023063021/stro-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:44:48.515710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"655e18d653ac01fb605c8461f44554140d0887c5","claim":"SUTRO BIOPHARMA, INC. reported financial results for the third quarter of 2023.","evidence_excerpt":"On November 13, 2023, Sutro Biopharma, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023063021/0000950170-23-063021-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}